Diabetes is primarily a self-managed disease that requires patients to perform multiple daily tasks. However, adherence to treatment may be negatively impacted by each patient's individual physical abilities, emotional issues, and lifestyle circumstances, although the “one size fits all” was necessary due to limited treatment options. This article reviews milestones of diabetes care, provides the rationale for individualizing diabetes management, and presents a potential roadmap for utilizing current and future technologies to transition from reactive medicine to proactive disease management and prevention in the future under the umbrella of individualized care.
Get full access to this article
View all access options for this article.
References
1.
JoslinEP.A Diabetic Manual of the Mutual Use of Doctor and Patient. 9th ed. Lea & Febiger: Philadelphia, PA; 1953; p. 153.
2.
DrashA.The control of diabetes mellitus: Is it achievable? Is it desirable?. J Pediatr, 1976; 88(6):1074–1076; doi: 10.1016/s0022-3476(76)81104-3
3.
ClarkeSF, FosterJR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci, 2012; 69(2):83–93.
4.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
5.
KarterAJ, AckersonLM, DarbinianJA, et al.Self-monitoring of blood glucose levels and glycemic control: The Northern California Kaiser Permanente Diabetes registry. Am J Med, 2001; 111(1):1–9.
6.
MoströmP, AhlénE, ImbergH, et al.Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. BMJ Open Diabetes Res Care, 2017; 5:e000342; doi: 10.1136/bmjdrc-2016-000342
7.
PuckreinGA, HirschIB, ParkinCG, et al.Assessment of glucose monitoring adherence in Medicare beneficiaries with insulin-treated diabetes. Diabetes Technol Ther, 2023; 25(1):31–38; doi: 10.1089/dia.2022.0377
8.
SiddiquiMH, KhanIA, MoyeenF, et al.Identifying barriers to therapeutic adherence in type 2-diabetes: A complex and multidimensional clinical issue. Asp Biomed Clin Case Rep, 2019; 2(1);22–28.
9.
DidyukO, Nicolas EconomN, GuardiaA, et al.Continuous glucose monitoring devices: Past, present, and future focus on the history and evolution of technological innovation. J Diabetes Sci Technol, 2020:1932296819899394; doi: 10.1177/1932296819899394
10.
RoterD.Which facets of communication have strong effects on outcome: A metaanalysis. In: Communicating with Medical Patients. (StewartM, RoterD. eds.) Sage: Newbury Park, CA; 1989.
11.
RoterDL, StewartM, PutnamSM, et al.Communication patterns of primary care physicians. JAMA, 1997; 227:350–356.
12.
CroomA, WiebeDJ, BergCA, et al.Adolescent and parent perceptions of patient-centered communication while managing type 1 diabetes. J Pediatr Psychol, 2011; 36:206–215.
13.
IannottiRJ, SchneiderS, NanselTR, et al.Self-efficacy, outcome expectations, and diabetes self-management in adolescents with type 1 diabetes. J Dev Behav Pediatr, 2006; 27:98–105.
14.
OttJ, GreeningL, PalardyN, et al.Self-efficacy as a mediator variable for adolescents adherence to treatment for insulin-dependent diabetes mellitus. Child Health Care, 2000; 29:47–63.
15.
BergCA, KingPS, ButlerJM, et al.Parental involvement and adolescents' diabetes management: The mediating role of self-efficacy and externalizing and internalizing behaviors. J Pediatr Psychol, 2011; 36:329–339.
16.
BergenstalRM, GargS, WeinzimerSA, et al.Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
17.
ForlenzaGP, Pinhas-HamielO, LiljenquistDR, et al.Safety evaluation of the minimed 670g system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther, 2019; 21(1):11–19.
18.
McAuleySA, LeeMH, PaldusB, et al.Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: A randomized, controlled trial. Diabetes Care, 2020; 43:3024–3033.
19.
BrownSA, KovatchevBP, RaghinaruD, et al.Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381(18):1707–1717.
20.
BrownSA, BeckRW, RaghinaruD, et al.Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: A randomized controlled trial. Diabetes Care, 2020; 43(8):dc200124; doi: 10.2337/dc20-0124
21.
BretonMD, KanapkaLG, BeckRW, et al.A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383:836–845.
22.
BrownSA, ForlenzaGP, BodeBW, et al.Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care, 2021; 44:1630–1640.
23.
CarlsonAL, SherrJL, ShulmanDI, et al.Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24(3):178–179.
24.
CollynsOJ, MeierRA, BettsZL, et al.Improved glycemic outcomes with medtronic MiniMed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care, 2021; 44(4):969–975; doi: 10.2337/dc20-225
25.
BergenstalRM, NimriR, BeckRW, et al.A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial. Lancet, 2021; 397(10270):208–219.
26.
TauschmannM, ThabitH, BallyL, et al.Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet, 2018; 392:1321–1329.
27.
BenhamouP-Y, FrancS, ReznikY, et al.Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: A 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health, 2019; 1:e17–e25.
28.
KariyawasamD, MorinC, CasteelsK, et al.Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: A randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health, 2022; 4(3):e158–e168.
29.
AbrahamMB, de BockM, SmithGJ, et al.Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: A randomized clinical trial. JAMA Pediatr 12 01, 2021; 175(12):1227–1235.
30.
BergenstalRM, GalRL, ConnorCG, et al.Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med, 2017; 167(2):95–102.
31.
ZieglerC, LibermanA, NimriR, et al.Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-logic artificial pancreas at home (DREAM4). J Diabetes Res, 2015; 2015:590308.
32.
CobryEC, KanapkaLG, CengizE, et al.Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Diabetes Technol Ther, 2021; 23(6):401–409; doi: 10.1089/dia.2020.0532
33.
BisioA, BrownSA, McFaddenR, et al.Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. Pediatr Diabetes, 2021; 22(3):495–502; doi: 10.1111/pedi.13164
34.
WheelerBJ, CollynsOJ, MeierRA, et al.Improved technology satisfaction and sleep quality with Medtronic MiniMed Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial. Acta Diabetol, 2022; 59(1):31–37; doi: 10.1007/s00592-021-01789-5
35.
KudvaYC, LaffelLM, BrownSA, et al.Patient-reported outcomes in a randomized trial of closed-loop control: The Pivotal International Diabetes Closed-Loop Trial. Diabetes Technol Ther, 2021; 23:673–683.
36.
CobryEC, BisioA, WadwaRP, et al.Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed loop system. Diabetes Care, 2022; 45(5):1292–1295; doi: 10.2337/dc21-1778
37.
MohanV, RadhaV. Precision diabetes is slowly becoming a reality. Med Princ Pract, 2019; 28(1):1–9; doi: 10.1159/000497241
38.
DennisJM.Precision medicine in type 2 diabetes: Using individualized prediction models to optimize selection of treatment. Diabetes, 2020; 69(10):2075–2085; doi: 10.2337/dbi20-0002
39.
SimsEK, BundyBN, StierK, et al.Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med, 2021; 13(583):eabc8980; doi: 10.1126/scitranslmed.abc8980
40.
MoraP, BuskirkA, LydenM, et al.Use of a novel, remotely connected diabetes management system is associated with increased treatment satisfaction, reduced diabetes distress, and improved glycemic control in individuals with insulin-treated diabetes: First results from the Personal Diabetes Management study. Diabetes Technol Ther, 2017; 19(12):715–722.
41.
SuD, MichaudTL, EstabrooksP, et al.Diabetes management through remote patient monitoring: The importance of patient activation and engagement with the technology. Telemed J E Health, 2019; 25(10):952–959.
42.
O'ConnorPJ, Sperl-HillenJM, RushWA, et al.Impact of electronic health record clinical decision support on diabetes care: A randomized trial. Ann Fam Med, 2011; 9(1):12–21.
43.
Sperl-HillenJM, RossomRC, KharbandaEO, et al.Priorities wizard: Multisite web-based primary care clinical decision support improved chronic care outcomes with high use rates and high clinician satisfaction rate. EGEMS (Wash DC), 2019; 7(1):9.
44.
International Diabetes Federation. IDF Diabetes Atlas, 9th ed. International Diabetes Federation: Brussels; 2019. Available from: www.diabetesatlas.org [Last accessed: February 8, 2020].
45.
World Health Organization (WHO). Draft Global Strategy on Human Resources for Health: Workforce 2030. World Health Organization: Geneva; 2016. Available from: https://www.who.int/health-topics/health-workforce#tab=tab_1 [Last accessed: March 3, 2020].
46.
FangM, WangD, CoreshJ, et al.Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Eng J Med, 2021; 384:2219–2228; doi: 10.1056/NEJMsa203227
47.
American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes—2023. Diabetes Care, 2023; 46 (Supplement 1):S97–S110.
48.
StoneMA, CharpentierG, DoggenK, et al.Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care, 2013; 36(9):2628–2638.
49.
MeneghiniL, MauricioD, OrsiE, et al.Achievement of HbA1c targets in the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) real-world study. ADA 77th Scientific Sessions 2017; Poster 990-P.
50.
MauricioD, MeneghiniL, SeufertJ, et al.Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabet Obes Metab, 2017; 19:1155–1164.
51.
KhuntiK, WoldenML, ThorstedBL, et al.Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care, 2013; 36:3411–3417.
52.
FaruqueLI, WiebeN, Ehteshami-Afshar, et al. Effect of telemedicine on glycated hemoglobin in diabetes: A systematic review and meta-analysis of randomized trials. CMAJ, 2017; 189:E341-64; doi: 10.1503/cmaj.150885
53.
SalehiS, OlyaeemaneshA, MobinizadehM, et al.Assessment of remote patient monitoring (RPM) systems for patients with type 2 diabetes: A systematic review and meta-analysis. J Diabetes Metab Disord, 2020; 19:115–127; doi: 10.1007/s40200-019-00482-3[Lastaccessed:June29,2020].
54.
TcheroH, KangambegaP, BriatteC, et al.Clinical effectiveness of telemedicine in diabetes mellitus: A meta-analysis of 42 randomized controlled trials. Telemed J E Health, 2019; 25(7):569–583.
55.
WangX, ShuW, DuJ, et al.Mobile health in the management of type 1 diabetes: A systematic review and meta-analysis. BMC Endocr Disord, 2019; 19:21; doi: 10.1186/s12902-019-0347-6
56.
CharpentierG, BenhamouPY, DardariD, et al.The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: A 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study). Diabetes Care, 2011; 34(3):533–539.
57.
DixonRF, ZisserH, LayneJE, et al.A smartphone-based type 2 diabetes clinic using video endocrinology consultations and CGM. J Diabetes Sci Technol, 2019; doi: 10.1177/1932296819888662
58.
LeeWC, BaluS, CobdenD, et al.Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clin Ther, 2006; 28(10):1712–1725.
59.
SuD, ZhouJ, KelleyMS, et al.Does telemedicine improve treatment outcomes for diabetes? A meta-analysis of results from 55 randomized controlled trials. Diabetes Res Clin Pract, 2016; 116:136–148.
60.
MarcolinoMS, MaiaJX, AlkmimMB, et al.Telemedicine application in the care of diabetes patients: Systematic review and meta-analysis. PLoS One, 2013; 8: e79246.
61.
LeeSWH, ChanCKY, ChuaSS, et al.Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis. Sci Rep, 2017; 7(1):12680; doi: 10.1038/s41598-017-12987-z
62.
HeitkemperEM, MamykinaL, TraversJ, et al.Do health information technology self-management interventions improve glycemic control in medically underserved adults with diabetes? A systematic review and meta-analysis. J Am Med Inform Assoc, 2017; 24:1024–1035.
63.
KeesaraS, JonasA, SchulmanK.Covid-19 and health care's digital revolution. N Engl J Med, 2020. [Epub ahead of print]; doi: 10.1056/NEJMp2005835
64.
GalindoRG, AleppoG, KlonoffDC, et al.Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol, 2020;1932296820932903; doi: 10.1177/1932296820932903
65.
JonesMS, GoleyAL, AlexanderBE, et al.Inpatient transition to virtual care during COVID-19 pandemic. Diabetes Technol Ther, 2020; 22(6):444–448.
66.
PetersAL, GargSK. The silver lining to COVID-19: Avoiding diabetic ketoacidosis admissions with telehealth. Diabetes Technol Ther, 2020; 22(60):449–453.
67.
WelshJB, ThomasR. Continuous glucose monitoring: An emerging standard of care. Am J Manag Care, 2019; 25(4 Spec No.):SP116–SP119.
